Drug Detail

Information about Navitoclax

Generic Name	Navitoclax
IND	ABT-263
Brand Name (US)
Manufacturer	Abbott
Drug Type
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	BCL-2 inhibitor